Express Pharma

USFDA issues CRL for proposed biosimilar Insulin-R: Biocon

The US Food and Drug Administration (USFDA) issues a Complete Response Letter (CRL) to convey to a company that its initial review of an application is complete and it cannot approve the application in its present form

1 179